Latest Hotspot

Vistagen's new drug, Fasedienol, reaches Phase 3 clinical trial endpoint, alleviating social anxiety disorder

10 August 2023
3 min read

On August 8, 2023, Vistagen announced the positive top-line results of the PALISADE-2 Phase 3 clinical trial, which assessed the efficacy and safety of its investigational fasedienol (PH94B, Aloradine) nasal spray in adult patients with social anxiety disorder (SAD). The analysis showed that the trial met its primary endpoint, with a statistically significant decrease in average Subjective Units of Distress Scale (SUDS) score during public speaking challenge in fasedienol group patients compared to placebo.

Fasedienol is a fast-acting neurosteroid candidate developed by Vistagen, which can modulate the olfactory-amygdala neural circuit of fear and anxiety, and attenuate the tension of the sympathetic autonomic nervous system, with the potential to treat postpartum anxiety, post-traumatic stress disorder, preoperative anxiety, panic disorder, and other anxiety-related diseases. The drug is administered intranasally in microgram doses, is tasteless, acts quickly (within 15 minutes), and is safe. Unlike existing antidepressants and benzodiazepines, the drug does not directly activate GABA-A receptors, nor does it directly act on the central nervous system of the brain.

ALISADE-2 is a multicenter, random double-blind, placebo-controlled phase 3 clinical trial in adult SAD patients. The trial (n=141) reached its primary efficacy endpoint, with patients receiving fasedienol (n=70) during treatment demonstrating a statistically significantly greater decrease in average SUDS scores (Least Squares [LS] mean = -13.8) compared to placebo (n=71, LS mean = -8.0), with a group difference of -5.8 (p=0.015). The trial also met its secondary endpoint, demonstrating a statistically significant difference between fasedienol and placebo in responder proportions assessed by clinicians using the Clinical Global Impressions-Improvement (CGI-I) scale (p=0.033). The trial showed fasedienol to be well tolerated, with no severe or serious adverse events (AEs). All treatment-emergent adverse events observed during the trial were mild or moderate severity.

According to the data disclosed by Synapse, as of August 9, 2023, Vistagen has 9 drugs under investigation, and has a very deep lineup in the field of nervous system drugs. Vistagen's new drug fasedienol has a very wide market space, and due to this drug, the company's stock price has surged many times. We look forward to the speedy release of fasedienol to bring new treatment options for "social phobic" patients.

Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part II
Advanced Tech.
5 min read
Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part II
10 August 2023
The success of CAR-T in hematologic malignancies lays the foundation for treating solid tumors, and oncology results will provide crucial knowledges for converting CAR-T to other diseases.
Read →
The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda
Drug Insights
9 min read
The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda
9 August 2023
the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?
Read →
Roche Clinical Trial Phase I of Oral Cyclic Peptide KRAS G12D Inhibitor
Roche Clinical Trial Phase I of Oral Cyclic Peptide KRAS G12D Inhibitor
10 August 2023
The KRAS G12D mutation affects approximately 180,000 patients in the United States and Europe, showing an incidence rate about 2.5 times higher compared to the KRAS G12C mutation.
Read →
Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part I
Advanced Tech.
6 min read
Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part I
9 August 2023
As research has progressed, CAR-T’s efficacy has been found to extend beyond cancer with great potential in treating autoimmunity, infections, fibrosis, aging-related diseases and more.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.